Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.91%
#2 Siren Siren +30.58%
#3 Purr Purr +28.61%
#4 OriginTrail OriginTrail +25.26%
#5 UnifAI Network UnifAI Network +16.95%
#6 Wrapped XPL Wrapped XPL +16.15%
#7 ApeX ApeX +15.83%
#8 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#9 Morpho Morpho +14.85%
#10 DigiByte DigiByte +14.48%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
設定
言語
日本
通貨
USD
テーマ
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
株式のランク #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
株価
$50.82
最終同期: 2026-08-11
時価総額
$102.09M
変化（1日）
1.90%
変化（1年）
-
国
US
取引 Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

カテゴリー

Healthcare
Hemab Therapeutics Holdings, Inc. Common Stock（COAG）の収益
Aug 2026 時点の収益 TTM: 0
Hemab Therapeutics Holdings, Inc. Common Stock の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Hemab Therapeutics Holdings, Inc. Common Stock の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH